Welcome
We will begin shortly...
Public Health Insights and Innovations
Self-Claim Attendance

Please **text** code **42223** to 317-671-8998 to record your attendance for your participation in this webinar.

You may text in 1 hour prior, during, and 4 hours after the end of the activity to record your attendance.

**Questions Please Contact:**
Division of Continuing Medical Education
317.274.0104 tel
cme@iu.edu
http://cme.medicine.iu.edu
CME Information

The Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Indiana University School of Medicine designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor.

There are no relevant financial relationships with ACCME-defined commercial interests for anyone who was in control of the content of this activity.
Opioid Use Disorder in Pregnancy

Tara Benjamin, MD, MS, FACOG
Assistant Clinical Professor
Department of Obstetrics & Gynecology
Division of Maternal-Fetal Medicine
Indiana University School of Medicine
Disclosure

• I have no disclosures
Learning Objectives

At the end of this presentation, participants should be better able to...

• Identify disease defining pathophysiologic changes of Opioid Use Disorder.

• Describe therapeutic options available for treatment in pregnant and non-pregnant patients.

• Understand the challenges in caring for pregnant women with Opioid Use Disorder.
Updates from Addiction Medicine
Jane Deaux

• 36yo G3P3 presents for annual exam.
• She has fibromyalgia managed with oxycodone.
• Her diagnosing physician retired.
• She’s worried about not having a prescriber.

Is this chronic pain or a substance use problem?
Terminology

• The (DSM-V) replaced “abuse” & “dependence” with **Substance Use Disorder (SUD)**.

• **SUD**- primary, chronic, & neurobiological disease with genetic, psychosocial & environmental factors influencing its development and manifestations.

• ____ Use Disorder (i.e. Alcohol, Cannabis).

• Is this chronic pain AND Opioid Use Disorder?
## Substance Use Disorder Diagnostic Criteria

<table>
<thead>
<tr>
<th>Impaired Control</th>
<th>Risky Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Using more or for longer than intended</td>
<td>8. Recurrent use in physically hazardous situations.</td>
</tr>
<tr>
<td>2. Desire to cut down/failed quit attempts</td>
<td>9. Continued use despite negative physical or psychological consequences</td>
</tr>
<tr>
<td>3. Lots of time spent using or recovering</td>
<td></td>
</tr>
<tr>
<td>4. Intense desire to use or cravings</td>
<td></td>
</tr>
</tbody>
</table>

### Social Impairment

<table>
<thead>
<tr>
<th>Social Impairment</th>
<th>Pharmacologic Dependence*</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. Failure to fulfill work, school, or home obligations</td>
<td>10. Tolerance</td>
</tr>
<tr>
<td>6. Use causes or exacerbates interpersonal problems.</td>
<td>11. Withdrawal symptoms with cessation</td>
</tr>
<tr>
<td>7. Reduction in important social, occupational, or recreational activities</td>
<td>*Diagnosis cannot be based on #s 10 &amp; 11 alone. At least one other is required.</td>
</tr>
</tbody>
</table>

Diagnosis requires the presence of at least 2 criteria over the past 12 months.

- Mild SUD = 2-3 criteria
- Moderate SUD = 4-5
- Severe SUD = 6 or more

ASAM Handbook of Addiction Medicine, 2016.
Jane Deaux-

• At her 2 week f/u, she signed a narcotic treatment agreement with you.
• You agreed to provide prescriptions & assess her bimonthly until her appt with pain mngmt.
• Today, 1 month later, she is accompanied by her significant other who is worried about her.
• You evaluate her for addictive behaviors.
• He informs you of the following:
Addictive Behaviors—since last visit

• Used illicit drugs
• Has hoarded meds
• Used more narcotic than prescribed
• Ran out of meds early
• Has increased use of narcotics

• Used analgesics PRN when prescription is for time limited use (i.e. used old Rx).
• Received narcotics from more than one provider
• Purchased meds from others.

Ms. Deaux’s behaviors

Wright, T. ACOG & ASAM Buprenorphine Course. 2016.
Addictive Behaviors- cont.

- Appears sedated or confused
- Worries about addiction
- Strong preference for a specific analgesic or route of admin.
- Concerned about future availability of narcotic.
- Worsened family relationships.
- Misrepresented analgesic or prescription use.

- “Needs” or “must have” meds.
- Discussion of meds was the predominant issue of visit.
- Lack of interest in rehab or self-management.
- Inadequate relief from analgesic.
- Indicated difficulty with using medication agreement.
- Significant others express concern over use of analgesics

Ms. Deaux’s behaviors

Wright, T. ACOG & ASAM Buprenorphine Course. 2016.
Jane Deaux

• Gets upset with her husband and abruptly leaves the office.
• Later that evening, the ER calls informing you that she is in severe acute opioid withdrawal.
• She was brought in by the police after arrest for shoplifting a breast pump she planned to exchange for heroin.
• Why has she behaved this way?
Chronic Disease
Stages of Addiction

- Binge and Intoxication
- Preoccupation & anticipation
- Stress & reward
- Withdrawal & negative affect

Response to drug

Binge & Intoxication

- Controlled Use
- Repeated Use
- CRAVINGS
- IMPULSIVE USE
- CONDITONING

DA cells no longer fire in response to reward, now in anticipation
Same mechanisms that strengthen memory formation

DA= dopamine
Nucleus accumbens

Withdrawal & Negative Affect

Repeated use → Smaller increases in DA

Sensitizes reward circuitry → Dysphoria

Increased reactivity to stress → Negative emotion

COMPULSIVE USE

Amygdala

Preoccupation & Anticipation

Neuroadaptations

Changes in the prefrontal cortex

Impaired executive functioning & inhibitory control

Ant cingulate gyrus
Orbitofrontal cortex
Ventral striatum

Decreased Capacity for:
- Self-regulation
- Decision making
- Flexibility in the selection of action
- Flexibility in the initiation of action
- Assignment of relative value
- Monitoring of error
- Resisting strong urges
- Following through on decision to stop

Management of Opioid Use Disorder
Jane Deaux

• Admits to having a problem
• Asks for help
OUD Management

Medically Supervised Withdrawal

Psychosocial Interventions

Medication-Assisted Treatment
Medically Supervised Withdrawal

- Cessation or dramatic opioid dose reduction.
- Spontaneous withdrawal*.
- Meds-opioid agonists, alpha-2 adrenergic agonists**.
- Titrate to dose that controls symptoms.
- Taper.

- Protocols available
- Immediate goals:
  1. Safe withdrawal
  2. Protect patient dignity
  3. Prepare for ongoing treatment
- One component of a comprehensive, ongoing treatment strategy.
- High relapse rate

*Objective withdrawal scales are available.
**Not FDA approved for withdrawal management.
ASAM Handbook of Addiction Medicine, 2016.
Psychosocial Treatment

- Brief interventions
- Motivational enhancement
- Self-Help Groups
- Drug Counseling
- Drug Courts
- Residential Treatment
- Analytic Psychotherapy
- Behavioral Therapy
- Cognitive-behavioral tx
- Coping skills tx
- Relapse prevention tx
- Network tx
- Mindfulness-based tx
- Contingency mngmt
- Community reinforcement

ASAM Handbook of Addiction of Medicine, 2016.
Medication-Assisted Treatment (MAT)

**Goals**

- Alleviate withdrawal
- Reduce complications
- Diminish cravings
- Stabilize neurochemistry

ASAM Handbook of Addiction Medicine, 2016.
Medication Assisted Treatment

- **Methadone**
  - Long-acting, **full opioid agonist** that is slowly metabolized and has high fat solubility.

- **Buprenorphine**
  - Short-acting, **partial opioid agonist** with high affinity, low intrinsic activity, and slow dissociation.

- **Naltrexone**
  - **Opioid antagonist** that blocks opioid receptors, preventing opioid binding & effects.

ASAM Handbook of Addiction Medicine, 2016.
Dose-response effect

- **Full agonist**, i.e., methadone
- **Partial agonist**, i.e., Buprenorphine
- **Antagonist**, i.e., Naltrexone

% mu Receptor Intrinsic activity

Log Dose

Wright, T. ACOG & ASAM Buprenorphine Course. 2016.
Methadone

- Oral onset of action 30-60 min
- Duration of action
  - 24-36 hours to treat OUD
  - 6-8 hours to treat pain.
- Dosing-Acute Withdrawal:
  - 10-30mg then 5 mg q6 prn.
  - Not to exceed 40mg in first 24hrs.
  - Administer 24hr requirement as a single dose the next day.
- Dosing-Maintenance:
  - Increase every 2-5 as needed
  - Goal of treatment is to reduce cravings and illicit use.

- Dispensing for OUD limited to licensed facilities.
- Daily nursing assessment, weekly counseling, random supervised drug testing, & psych services available.
- Low overdose risk.
- Abuse potential with prescriptions for pain.
- Pregnant women on higher doses are less likely to relapse.

Wright, T. ACOG & ASAM Buprenorphine Course. 2016.
Buprenorphine

- Sublingual tablets and films.
- **“Combo”** (bup/naloxone).
- **“Mono”** (buprenorphine only).
  - Approved for mod-severe OUD
  - **OFF LABEL** for pain
- Parenteral and transdermal patch.
  - Approved for pain
  - Not approved for OUD
- Standard urine drug screen won’t be opioid positive.

- Prescribers required to complete 8hr CME & apply for a DEA waiver.
  - [www.samhsa.gov](http://www.samhsa.gov)
- Overdose risk minimal.
- Abuse potential less than with full opioid agonists.
- Most illicit use is to prevent or treat withdrawal and cravings.
- Buprenorphine and high-potency benzodiazepines...DEATH.
- Less NAS

Comer, S, Addiction. 2010.  
Buprenorphine Dosing

• **Acute Withdrawal:**
  - Optimal regimen not established.

• **Induction:**
  - 4mg when COWS >/= 8
  - Increase by 2mg q2-4h as needed.

**Day 2**

• If day 1 total was 8-12mg, give 8mg. If symptoms, give 12mg.
• If symptoms return later in the day, give 4mg.
• Try not to dose beyond 16mg during induction.
• DC with 1 week f/u
  - Continue titration outpatient
  - Max dose may exist in some states
  - Research needed

Expert Opinion, President’s Workshop on OUD in Pregnancy, SMFM, 2018
Purpose of Naloxone in Combination Product

- Limited oral & sublingual bioavailability
- Active when injected (SQ, IM, or IV).
- If the combo product is crushed, dissolved, and injected:
  - Naloxone will block the opioid agonist effect of buprenorphine.
  - This causes withdrawal if opioid dependent.
  - Decreases misuse.
  - Safer if diverted.

Wright, T. ACOG & ASAM Buprenorphine Course. 2016.
Pregnancy: Myths & Management
Jane Deaux

• Positive urine pregnancy test during admission.
• Discharged with a prescription for buprenorphine instead of buprenorphine/naloxone.
• She calls with questions about “detox” due to neonatal concerns.

• She also desires detox because her family has told her:
  • Bup is just a legal form of heroin.
  • Baby will be born addicted.
  • If she cares about her baby, she would just stop using anything.
MYTH ONE

MAT is just a legal form of heroin

6-8 hrs

Normal

Heroin, Pain pills

Normal

Negative Affect & Withdrawal

Buprenorphine

Methadone

Negative Affect & Withdrawal

Normal

Negative Affect & Withdrawal

Normal
MYTH TWO

[Image: Blue cross with text 'MYTH']
Neonatal Opioid Withdrawal Syndrome

- Aka Neonatal Abstinence Syndrome (NAS)
- Symptoms that occur in newborns with in utero exposure to opioids.
- MAT dosage does not correlate with onset or severity.
- Mild symptoms can be managed with supportive care measures, while more severe symptoms require pharmacologic intervention.
- Can result in NICU admission (though not required) and prolonged hospital stay.
- Self-limited condition with no PROVEN long term effects.
...If she cares about her baby, she should just stop (detox).
OUD Management in pregnancy

- Medically Supervised Withdrawal (MSW)
- Psychosocial Interventions
- Medication-Assisted Treatment
  - No Naltrexone
Historically, why has detox not been recommended in pregnancy?
Narcotic withdrawal in pregnancy: Stillbirth incidence with a case report

José Luis Rementeria, M.D.
Nemesio N. Nunag, M.D.
Bronx, New York

A stillborn infant was born to a drug-addicted mother who had withdrawal symptoms shortly before delivery. Mechanisms are presented to help explain the possible relationship between the maternal withdrawal and the fetal death. Statistics are also presented to show an increased stillborn and neonatal mortality rate in the over-all pregnant drug-addicted population.
Fetal stress from methadone withdrawal

FREDERICK P. ZUSPAN, M.D.
JANIS A. GUMPEL, M.D.
ALFONSO MEJIA-ZELAYA, M.D.
JOHN MADDEN, M.D.
ROY DAVIS, D.M.N.
With the technical assistance of
MARGARET FILER, B.A.
ADEL TIAMSON, B.A.
Chicago, Illinois

A pregnant patient in the midtrimester of pregnancy was begun on a methadone detoxification program. The fetal neurobiologic response was monitored by serial amniotic fluid amines (epinephrine and norepinephrine). The detoxification program showed a marked fetal response of the adrenal gland (E) and sympathetic nervous system (NE) that was blunted when the methadone dose was increased. Detoxification during pregnancy is not recommended unless the fetus can be biochemically monitored.
## Medically Supervised Withdrawal in Pregnancy: Contemporary Data

<table>
<thead>
<tr>
<th>Study</th>
<th># pts / # yrs</th>
<th>Outcomes: Methadone Detoxification in Pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maas et al, 1990</td>
<td>57 / 7</td>
<td>17 (30%) became drug free. <strong>No adverse outcomes</strong> due to detox reported.</td>
</tr>
<tr>
<td>Dashe et al, 1998</td>
<td>34 / 7</td>
<td>20 (59%) successful. <strong>No fetal distress or demise.</strong> 4 went into labor (3 at 36wks, 1 at 37wks).</td>
</tr>
<tr>
<td>Luty et al, 2003</td>
<td>101 / 12</td>
<td>One 1st trim SAB. 2 perinatal deaths. 34 neonates &lt;2500g. One delivery &lt;37wks. <strong>(50% of pts were actively using heroin.)</strong></td>
</tr>
<tr>
<td>Jones et al. 2008</td>
<td>175 / 4</td>
<td><strong>No increased risk</strong> in preterm birth or fetal loss.</td>
</tr>
<tr>
<td>Stewart et al, 2013</td>
<td>95 / 6</td>
<td>53 (56%) successful. <strong>No fetal distress or demise.</strong></td>
</tr>
<tr>
<td>Bell et al, 2016</td>
<td>301</td>
<td>53 (17.6%) prior to 37 weeks. <strong>No adverse outcomes.</strong></td>
</tr>
</tbody>
</table>

Contemporary Data Shows

• Detox may be safe in pregnancy, BUT...

• Low rates of detox completion.
• High rates of post-treatment relapse.
• Relapse is associated with increased risk for HIV, hepatitis, overdose, and death.

• Detox for prevention of NAS is not supported.

Wright, T. ACOG & ASAM Buprenorphine Course. 2016.
If the alternative to medically supervised withdrawal is continued illicit drug use, then detox is preferable. ACOG Committee Opinion No. 524, 2012.
Other Management Considerations: Antepartum

- Coordinated care between OB, Addiction medicine, Behavioral health → MFM not required!
- Increased or split dosing may be required.
- Avoid benzodiazepines, and other CNS depressants.
- Overdose education/Narcan kit.

- Counsel on measures for NAS reduction, contraception, breastfeeding
- Screen for: Intimate partner violence (IPV), adverse childhood events (ACE)
- Assess social determinants of health
- Ultrasound
- Growth scan 28-32 weeks (unless an indication for serial scans exists)

Expert Opinion, President’s Workshop on OUD in Pregnancy, SMFM, 2018
Other Management Considerations: Antepartum

- TB skin testing
- Test for Hepatitis C
- Assess Hepatitis A/B immunity → vaccinate if necessary
- EKG if methadone dose ≥ 120mg
- Echo for history of endocarditis

- Dental care
- GI referral for Hepatitis C
- Consider anesthesia consult, pediatrics consult
- Shared decision making: postpartum pain management
- Use ASAM Criteria to establish level of care → residential, intensive outpatient, partial hospitalization, outpatient

Expert Opinion, President’s Workshop on OUD in Pregnancy, SMFM, 2018
Other Management Considerations: Intrapartum

- Timing of delivery:
- Deliver for obstetric indications if stable in treatment.
- Consider early term delivery for ongoing illicit use & non-adherence.

- Continue MAT
- Avoid mixed opioid agonist-antagonists (butorphanol, nalbuphine, pentazocine).
- Neuraxial anesthesia recommended.

Expert Opinion, President’s Workshop on OUD in Pregnancy, SMFM, 2018
Other Management Considerations: Postpartum

- Best practice for dosing reduction is undetermined (research needed).
- Ensure maternal stability in recovery.
- Ensure smooth transition of care.
- Ensure postpartum f/u with GI for Hepatitis C.
- Consider expanding Medicaid for up to a year postpartum.

Expert Opinion, President’s Workshop on OUD in Pregnancy, SMFM, 2018
Optimal Care

- Highlights the chronic nature of the disease
- Woman-centered
- Trauma-informed
- Family support
- Comprehensive
- Mother-infant dyad
- Co-location of services

- Pediatrics
- Addiction Psych/Addiction Med
- Obstetrics
- Psychiatry
- Case management
- Behavioral Therapy/Counseling
- Peer support groups
Challenges in Care

• Late prenatal care
• Lack of Addiction Psychiatrists, Addiction Medicine Specialists, and providers with waivers to prescribe buprenorphine in IN.
• Few providers who will prescribe buprenorphine for pregnant women.
• Few providers who will accept “pregnancy medicaid.”
• Few Methadone Clinics/Inhibitory practices.
Challenges in Care

• Treating co-occurring psych diagnoses.
• Transitioning to a postpartum provider.
• Few inpatient rehabilitation facilities that will accept pregnant women or newly delivered women with their newborns.
• Substance use disorders are still viewed by many as a moral failure rather than a chronic disease.
Jane Deaux

- Delivers a 7lb. Boy at 38+9 weeks.
- Hospital stay is 13 days due to Neonatal Abstinence Syndrome......

That’s a talk for another day!
Take home points

• Opioid Use Disorder
  - Relapsing, remitting chronic disease
  - Pathophysiologic changes in the brain
  - Treatment available

• Medication Assisted Treatment is effective, safe, and preferred during pregnancy.

• There are challenges to care for all patients, but particularly for pregnant patients.
Take home points

- Opioid Use Disorder
  - Relapsing, remitting chronic disease
  - Pathophysiologic changes in the brain
  - Treatment available

- Medication Assisted Treatment is effective, safe, and preferred during pregnancy.

- There are challenges to care for all patients, but particularly for pregnant patients.
Questions

- [www.samhsa.gov](http://www.samhsa.gov) for more information on:
  - Obtaining a DEA waiver.
  - Physicians with DEA waivers by state.
  - Treatment programs by state.